Xbrane Biopharma AB (publ) (STO:XBRANE)

Sweden · Delayed Price · Currency is SEK

9.56

-0.16 (-1.65%)

Aug 13, 2026, 5:23 PM CET

Xbrane Biopharma AB Financials Overview

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	76.45	152.35	148.1	238.73	57.62	10.71
Revenue Growth	-66.36%	2.87%	-37.96%	314.33%	438.03%	-
Gross Profit	43.43	89.55	129.87	35.39	57.62	10.71
Operating Income	-66.42	-28.25	-97.22	-296.72	-152.65	-176.46
Net Income	106.01	127.24	-266.22	-388.17	-172.51	-188.38
Earnings Per Share	-0.60	0.08	-0.22	-82.50	-843.75	-997.50
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Germany	82.7	67.5	66.5	209.9
India	-	84.3	54.1	-
Others	0.5	0.6	1.1	-
North America	-	-	26.4	28.7
Total	83.4	152.4	148.1	238.6

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	66.75	86.59	124.33	65.4	193.99	295.18
Total Debt	56.88	58.31	191.72	231.48	38.22	44.38
Net Cash (Debt)	9.87	28.28	-67.39	-166.08	155.77	250.8
Net Cash Growth	-	-	-	-	-37.89%	5.88%
Net Cash Per Share	0.01	1.72	-4.10	-35.06	761.51	1328.76

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-190.55	-250.69	-133.73	-406.68	-193.92	-219.61
Capital Expenditures	-	-	-0.5	-6.79	-11.62	-27.68
Free Cash Flow	-190.55	-250.69	-134.23	-413.47	-205.53	-247.29
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	56.81%	58.77%	87.69%	14.82%	100.00%	100.00%
Operating Margin	-86.87%	-18.54%	-65.65%	-124.29%	-264.94%	-1647.74%
Pretax Margin	-99.25%	-28.84%	-87.59%	-134.89%	-292.47%	-1710.95%
Profit Margin	-102.29%	-30.30%	-95.42%	-134.89%	-292.47%	-1710.95%
FCF Margin	-249.23%	-164.55%	-90.64%	-173.20%	-356.72%	-2309.16%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	127.50	-	-	-	-
Forward PE	-	2.45	18.40	27.74	13.18	20.01
PS Ratio	2.36	1.38	207.58	0.14	4.44	27.78